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Abstract
© 2018 Marina Gomzikova et al. Extracellular vesicles (EV) represent a promising vector system
for biomolecules and drug delivery due to their natural origin and participation in intercellular
communication. As the quantity of EVs is limited, it was proposed to induce the release of
membrane  vesicles  from  the  surface  of  human  cells  by  treatment  with  cytochalasin  B.
Cytochalasin B-induced membrane vesicles (CIMVs) were successfully tested as a vector for
delivery of dye, nanoparticles, and a chemotherapeutic. However, it remained unclear whether
CIMVs possess fusion specificity with target cells and thus might be used for more targeted
delivery of therapeutics. To answer this question, CIMVs were obtained from human prostate
cancer PC3 cells. The diameter of obtained CIMVs was 962,13 ± 140,6 nm. We found that there
is no statistically significant preference in PC3 CIMVs fusion with target cells of the same type.
According to our observations, the greatest impact on CIMVs entry into target cells is by the
heterophilic interaction of CIMV membrane receptors with the surface proteins of target cells.
http://dx.doi.org/10.1155/2018/7053623
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